PM
IONS icon

Parametrica Management’s Ionis Pharmaceuticals IONS Stock Holding History

Parametrica Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,165
Closed -$228K – 119
2022
Q2 		$228K Buy
+6,165
New +$232K 0.25% 112
2019
Q1 		– Sell
-4,161
Closed -$225K – 241
2018
Q4 		$225K Buy
+4,161
New +$212K 0.27% 200
2017
Q3 		– Sell
-5,849
Closed -$298K – 390
2017
Q2 		$298K Buy
+5,849
New +$272K 0.28% 138

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Parametrica Management's IONS Position: Q3 2022 in Review

Parametrica Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 6,165 shares — an estimated $228K sold.

Parametrica Management first reported a position in IONS in Q2 2017 and held it in 3 quarters. The position peaked at $298K in Q2 2017. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

  • Parametrica Management reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Parametrica Management sold 6,165 Ionis Pharmaceuticals shares in Q3 2022, an estimated $228K.
  • Parametrica Management first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Parametrica Management's Ionis Pharmaceuticals position peaked at $298K in Q2 2017.
  • 349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Parametrica Management's 13F filing for Q3 2022, filed 3 Nov 2022.